Table Graph
      published meta-analysis   sensitivity analysis   studies

Nuvaxovid (NVX-CoV2373) Novavax in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias confirmed COVID (any severity)detailed resultsNovavax PREVEND-19 phase 3 US (2019nCoV-301), 2021 0.10 [0.05; 0.17] 0.10[0.05; 0.17]Novavax PREVEND-19 phase 3 US (2019nCoV-301), 202110%NAnot evaluable symptomatic Covid-19detailed resultsNovavax phase 2 South Africa (2019nCoV-501), 2021 0.51 [0.27; 0.94] Novavax phase 3 UK (2019nCoV-302), 2021 0.10 [0.05; 0.20] 0.23[0.05; 1.09]Novavax phase 2 South Africa (2019nCoV-501), 2021, Novavax phase 3 UK (2019nCoV-302), 2021292%2,684lownot evaluable severe COVID-19 occurrencedetailed resultsNovavax phase 2 South Africa (2019nCoV-501), 2021 0.49 [0.02; 14.58] 0.49[0.02; 14.58]Novavax phase 2 South Africa (2019nCoV-501), 202110%2,684NAnot evaluable Potential Immune Gastrointestinal disordersdetailed resultsKeech, 2020 0.50 [0.02; 14.81] 0.50[0.02; 14.81]Keech, 202010%1,198NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-04-30 20:57 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 764 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons